| アブストラクト | BACKGROUND: In May 2021, the U.S. Food and Drug Administration expanded the Emergency Use Authorization for the Pfizer-BioNTech mRNA Coronavirus disease 2019 (COVID-19) Vaccine (BNT162b2) to include adolescents 12-15 years of age. As vaccine administration continues to increase, potential adverse outcomes, to include myocarditis, are being reported to the Vaccine Adverse Event Reporting System. CASE REPORT: This case report describes a 17-year-old male patient who developed focal myocarditis mimicking an ST-segment elevation myocardial infarction (STEMI) 3 days after administration of an mRNA COVID-19 vaccine. Why Should an Emergency Physician Be Aware of This? Myocarditis is a rare complication in adolescents receiving mRNA COVID-19 vaccines. Focal myocarditis may demonstrate localizing electrocardiographic changes consistent with a STEMI. Overall, complications of the mRNA COVID-19 vaccines are extremely rare. The vaccine continues to be recommended by public health experts, as the benefits of vaccinations greatly outweigh the rare side effects. |
|---|
| ジャーナル名 | The Journal of emergency medicine |
|---|
| Pubmed追加日 | 2021/11/11 |
|---|
| 投稿者 | Azir, Michael; Inman, Brannon; Webb, James; Tannenbaum, Lloyd |
|---|
| 組織名 | Department of Emergency Medicine, San Antonio Uniformed Services Health Education;Consortium, Fort Sam Houston, Texas. Electronic address: michaelazir@gmail.com.;Consortium, Fort Sam Houston, Texas. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/34756746/ |
|---|
